StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)

Analysts at StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The stock has a market cap of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 52-week low of $0.01 and a 52-week high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.